Muscle Weakness: What Could Be Causing It?

True Weakness vs. Fatigue: The First Clinical Question

The single most important distinction is whether a patient has objective, measurable loss of muscle strength or subjective fatigue that feels like weakness. True weakness means a muscle cannot generate normal force against resistance. Fatigue means the patient feels exhausted but can still produce normal strength on examination.

This matters because the differential diagnosis splits sharply at this fork. A 2019 review in BMJ Best Practice noted that fatigue accounts for the presenting complaint in up to 25% of all primary care visits, while true neuromuscular weakness is far less common [1]. Fatigue-predominant complaints point toward systemic conditions: depression, sleep disorders, anemia, chronic infection, or poorly controlled diabetes. True weakness points toward neuromuscular, endocrine, or structural causes.

A simple bedside test helps. Ask the patient to rise from a seated position without using their hands, walk on heels and toes, and hold both arms overhead for 60 seconds. Inability to perform these tasks suggests objective proximal or distal weakness and warrants a focused workup [2]. The pattern of weakness (proximal vs. distal, symmetric vs. asymmetric, upper vs. lower motor neuron signs) then narrows the differential considerably.

Endocrine and Hormonal Causes

Hormonal imbalances are among the most common and most treatable causes of muscle weakness. Hypothyroidism, testosterone deficiency, cortisol excess, and growth hormone decline all produce measurable changes in muscle mass and function.

Hypothyroidism causes a myopathy characterized by proximal weakness, muscle stiffness, cramps, and elevated creatine kinase (CK). A cross-sectional study published in the Journal of Clinical Endocrinology & Metabolism found that 79% of hypothyroid patients reported muscle symptoms and 38% had objectively reduced grip strength compared to euthyroid controls [3]. TSH and free T4 testing identifies this readily. Levothyroxine replacement reverses the myopathy in most patients within 3 to 6 months.

Low testosterone produces sarcopenia-pattern weakness with loss of lean mass, reduced grip strength, and slower gait speed. The Endocrine Society's 2018 clinical practice guideline defines testosterone deficiency as a total testosterone level below 300 ng/dL measured on two morning samples, combined with symptoms [4]. A meta-analysis of 37 RCTs (N=3,393) published in JAMA Internal Medicine found that testosterone therapy increased lean body mass by an average of 1.6 kg and improved lower-extremity strength compared to placebo [5]. Women in perimenopause and menopause also experience testosterone decline, though reference ranges differ.

Cushing syndrome (endogenous or exogenous from chronic glucocorticoid use) causes a distinctive proximal myopathy affecting the pelvic girdle and thighs. Patients often report difficulty climbing stairs or rising from a chair. Exogenous steroid myopathy is dose-dependent and particularly common with fluorinated glucocorticoids like dexamethasone [6].

Vitamin D Deficiency and Muscle Function

Vitamin D deficiency is one of the most under-recognized causes of proximal muscle weakness, particularly in older adults, people with darker skin, and those living at higher latitudes.

Vitamin D receptors (VDR) are expressed in skeletal muscle tissue, and 1,25-dihydroxyvitamin D directly influences type II (fast-twitch) muscle fiber size and contractile function. A systematic review and meta-analysis published in the Journal of the American Geriatrics Society (20 RCTs, N=5,849) found that vitamin D supplementation reduced fall risk by 19% in adults aged 65 and older with baseline levels below 20 ng/mL [7]. Falls are a direct consequence of proximal weakness in this population.

The threshold matters. Serum 25-hydroxyvitamin D levels below 20 ng/mL (50 nmol/L) are classified as deficient by the Endocrine Society, and levels between 20 and 29 ng/mL as insufficient [8]. A NHANES analysis found that approximately 42% of U.S. adults have levels below 20 ng/mL, with rates exceeding 80% in Black Americans [9]. Repletion protocols typically involve 50 to 000 IU of ergocalciferol or cholecalciferol weekly for 8 weeks followed by maintenance dosing of 1,500 to 2 to 000 IU daily. Strength improvements are measurable within 8 to 12 weeks of achieving a 25-OH level above 30 ng/mL.

Medication-Induced Myopathy

Several widely prescribed medications cause muscle weakness. Statins are the most common culprit.

Statin-associated muscle symptoms (SAMS) range from myalgia (pain without weakness) to true myopathy (weakness with CK elevation) to the rare but life-threatening rhabdomyolysis. A 2022 meta-analysis in The Lancet of 19 large statin trials (N=123,940) found that statins caused a 3% absolute increase in muscle pain or weakness compared to placebo over a median of 4.3 years [10]. The nocebo effect may inflate real-world complaint rates. Still, true statin myopathy (CK elevation above 4x the upper limit of normal) occurs in roughly 1 in 1,000 to 1 in 10,000 treated patients [10].

Dr. Robert Rosenson, a cardiologist at Mount Sinai and co-author of the American Heart Association's scientific statement on statin safety, has stated: "The key is distinguishing true myopathy from myalgia. If CK is normal and weakness is not objective, the statin is unlikely to be the cause" [11].

Other medications that cause myopathy include:

• Glucocorticoids (chronic use, as above)
• Colchicine (proximal myopathy with vacuolar changes, often missed)
• Antiretrovirals (zidovudine causes mitochondrial myopathy)
• Immune checkpoint inhibitors (nivolumab, pembrolizumab) cause an inflammatory myositis in 1 to 3% of patients [12]
• Fluoroquinolones (tendon and muscle toxicity, FDA black box warning)

A thorough medication review is a non-negotiable step in any muscle weakness evaluation.

Neurological Causes: When to Escalate

Neurological conditions produce the most serious forms of muscle weakness. Pattern recognition is the key to identifying them.

Myasthenia gravis (MG) causes fluctuating, fatigable weakness that worsens with repetitive use and improves with rest. Ocular symptoms (ptosis, diplopia) are the presenting complaint in roughly 50% of cases [13]. Serum acetylcholine receptor (AChR) antibodies are positive in approximately 85% of generalized MG patients. The prevalence is estimated at 14 to 20 per 100,000 persons in the United States [13].

Inflammatory myopathies (polymyositis, dermatomyositis, inclusion body myositis) cause progressive proximal weakness, often with elevated CK levels ranging from 5 to 50 times the upper limit of normal. Dermatomyositis adds characteristic skin findings (heliotrope rash, Gottron papules). A population-based study in Olmsted County, Minnesota found an incidence of 9.5 per million person-years for inflammatory myopathies [14]. Muscle biopsy remains the gold standard for diagnosis. Treatment involves immunosuppression: high-dose prednisone plus a steroid-sparing agent such as methotrexate or azathioprine.

Amyotrophic lateral sclerosis (ALS) produces progressive asymmetric weakness with both upper and lower motor neuron signs (fasciculations, hyperreflexia, atrophy co-existing). Mean survival from symptom onset is 3 to 5 years. Riluzole and edaravone provide modest slowing of progression [15]. Rapid, unexplained asymmetric weakness in a patient over 50 with fasciculations should prompt immediate neurology referral.

The American Academy of Neurology recommends electrodiagnostic testing (EMG and nerve conduction studies) when the clinical picture suggests a neuromuscular disorder that is not explained by initial laboratory evaluation [16].

GLP-1 Receptor Agonists, Weight Loss, and Muscle Mass

Patients on GLP-1 receptor agonists like semaglutide and tirzepatide frequently ask about muscle loss. The concern is legitimate.

In the STEP 1 trial (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo [17]. Body composition sub-analyses from STEP 1 using DXA scans showed that approximately 40% of total weight lost was lean mass [18]. This ratio is consistent with caloric restriction in general and is not unique to GLP-1 therapy, but it means that a patient losing 30 pounds may lose roughly 12 pounds of lean tissue.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center, has noted: "The lean mass loss seen with GLP-1 agonists is proportional to what we see with diet-induced weight loss. Resistance exercise is the single most effective countermeasure" [19].

Resistance training at least 2 to 3 sessions per week and protein intake of 1.2 to 1.6 g/kg/day are recommended during pharmacological weight loss to preserve muscle. Concurrent testosterone optimization in hypogonadal patients may provide additional protection against lean mass loss, though large RCTs combining TRT with GLP-1 therapy are still underway.

The Diagnostic Workup: A Step-by-Step Approach

A structured approach prevents both missed diagnoses and unnecessary testing. The workup proceeds in tiers.

Tier 1 (all patients with true weakness): Complete blood count, comprehensive metabolic panel (including calcium, potassium, magnesium), serum CK, TSH, free T4, 25-hydroxyvitamin D, ESR or CRP, and a thorough medication review. These tests are inexpensive and identify the most common causes. Total testosterone (morning draw) should be included for men over 40 or women with other signs of androgen deficiency.

Tier 2 (if Tier 1 is unrevealing or clinical suspicion is high): AChR antibodies (if fatigable weakness), ANA and myositis-specific antibodies (Jo-1, Mi-2, MDA5) if CK is elevated without medication cause, serum and urine protein electrophoresis (if age above 50 with unexplained neuropathy), and HbA1c (diabetic amyotrophy). Aldolase can supplement CK if inflammatory myopathy is suspected.

Tier 3 (neurology referral): EMG and nerve conduction studies, MRI of affected muscle groups (for inflammatory myopathies), and muscle biopsy when non-invasive testing is inconclusive. Genetic testing is appropriate when hereditary myopathy is suspected based on family history and pattern of weakness.

This tiered approach is consistent with the diagnostic framework recommended by the American Academy of Family Physicians for the evaluation of muscle weakness in the primary care setting [20].

Treatment Depends Entirely on the Cause

There is no single treatment for muscle weakness. Therapy is cause-specific.

Hypothyroid myopathy resolves with thyroid hormone replacement. Vitamin D deficiency responds to repletion. Statin myopathy requires dose reduction, drug switching (pravastatin and rosuvastatin have lower myopathy rates), or discontinuation with re-challenge. Testosterone replacement in men with confirmed deficiency (below 300 ng/dL on two morning samples) increases lean mass and strength within 3 to 6 months of achieving physiologic levels [4][5].

For inflammatory myopathies, first-line treatment is prednisone 1 mg/kg/day with taper over 6 to 12 months plus a steroid-sparing immunosuppressant. Rituximab is used in refractory cases. For MG, pyridostigmine provides symptomatic relief, while long-term management involves immunosuppression and, in selected cases, thymectomy. The MGTX trial (N=126) showed that thymectomy plus prednisone was superior to prednisone alone over 3 years, reducing the need for immunosuppressive drugs [21].

For patients experiencing weakness from rapid weight loss (including GLP-1 agonist therapy), the prescription is straightforward: progressive resistance exercise, adequate protein, and monitoring of hormonal status. These interventions have strong evidence and no meaningful downside.

The most important treatment principle across all causes is this: speed of diagnosis determines outcomes. A 2020 retrospective study in Neurology found that the median time from symptom onset to diagnosis for inflammatory myopathies was 7.7 months, and each month of diagnostic delay was associated with worse functional outcomes at 2 years [22]. If something does not feel right, get tested.